Protocol Ledger

NCT05197192 · Phase III · RECRUITING

A Phase-3-trial of Acalabrutinib, Obinutuzumab & Venetoclax Compared to Obinutuzumab and Venetoclax in Previously Untreated Patients With High Risk CLL

Interventional Phase III clinical trial protocol NCT05197192 sponsored by German CLL Study Group in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2022-04-19 Enrollment: 202 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT05197192
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)202 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)1 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05197192
Protocol FieldVerified Registry Value
NCT IdentifierNCT05197192
Consolidated Lead SponsorGerman CLL Study Group
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment202 participants (ESTIMATED)
Registered Start Date2022-04-19
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT05197192
Hospital Research SiteLocationSite Profile
Universitaetsklinikum EssenEssen, GermanyOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI